Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Bankruptcy filing of a large national retail REIT; Restructuring of Mortgage debt
Assist special servicers with interpreting provisions in applicable pooling and servicing agreements, intercreditor agreements, participation more
Acquisition program of data management and destruction companies for Recall Corporation
Represented Recall Corporation and its subsidiaries in an acquisition program of data management and destruction companies in U.S. and Canadian more
Competitor acquisition of Global Knowledge Training LLC
The firm advised Global Knowledge Training LLC, the world's largest privately held provider of training and enterprise learning services for more
Waste management, product stewardship and air quality issues for a specialty tape manufacturer
Represented a manufacturer of commodity, industrial grade and specialty adhesives tapes regarding a wide range of environmental issues, including more